IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Clinical trial NCT06119685 · RECRUITING

Trial details

NCT number: NCT06119685
Sponsor: Indapta Therapeutics, INC.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

NHL Multiple Myeloma Blood Cancer Refractory Non-Hodgkin Lymphoma Relapsed Non-Hodgkin Lymphoma Refractory Multiple Myeloma Relapsed Multiple Myeloma

Start date: 2023-10-25
Primary completion: 2025-12-30
Enrollment: 128

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.